NCT06504368View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

December 31, 2027

Conditions

Solid Tumors, Adult

Interventions

DRUG

DCR-PDL1

Solution for IV Infusion

Trial Locations (1)

78229

RECRUITING

Next Oncology, San Antonio

All Listed Sponsors

lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY